Cocrystal Pharma Inc. has released an investor presentation detailing its advancements in developing potent antivirals targeting serious diseases, including influenza, norovirus, and coronavirus. The company utilizes a proprietary drug discovery platform developed with Nobel Prize-winning technology to create broad-spectrum antiviral drugs. Current programs include an oral influenza PB2 inhibitor (CC-42344), progressing in Phase 2a studies, and a dual oral norovirus and coronavirus protease inhibitor (CDI-988), which has completed Phase 1 studies. Cocrystal Pharma is also exploring collaboration opportunities for pandemic preparedness and is led by a seasoned team including Nobel laureates. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.